Vaxil Bio Ltd. VXL.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 184.90K | -- | -- | -- | 114.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 184.90K | -- | -- | -- | 117.70K |
| Operating Income | -184.90K | -- | -- | -- | -117.70K |
| Income Before Tax | 268.00K | -- | -- | -- | -49.20K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.27 | -- | -- | -- | -0.05 |
| Earnings from Discontinued Operations | 2.20K | -- | -- | -- | -20.90K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 270.20K | -- | -- | -- | -70.00K |
| EBIT | -184.90K | -- | -- | -- | -117.70K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.09 | -- | -- | -- | -0.03 |
| Normalized Basic EPS | -0.03 | -- | -- | -- | -0.01 |
| EPS Diluted | 0.09 | -- | -- | -- | -0.03 |
| Normalized Diluted EPS | -0.03 | -- | -- | -- | -0.01 |
| Average Basic Shares Outstanding | 13.83M | -- | -- | -- | 10.96M |
| Average Diluted Shares Outstanding | 13.83M | -- | -- | -- | 10.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |